Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | AAK1 | Q2M2I8 | 6/20 | 0.33 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 3/20 | 0.33 |
| ▸ | CA1 | P00915 | 3/20 | 0.33 |
| ▸ | CA2 | P00918 | 3/20 | 0.33 |
| ▸ | CA9 | Q16790 | 3/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | JAK1 | P23458 | 1/20 | 0.32 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18921432 | 0.84 | CTSS (0.40) | — | |
| SCHEMBL18921411 | 0.83 | EPHX2 (0.40) | FOLH1EPHX2 | |
| SCHEMBL21783498 | 0.79 | ADRB1 (0.34) | AAK1CA12CA1CA2CA9 | |
| SCHEMBL22232743 | 0.79 | RIPK1 (0.50) | CA12CA1 | |
| SCHEMBL22456387 | 0.79 | RIPK1 (0.50) | CA12CA1 | |
| SCHEMBL18921533 | 0.79 | RIPK1 (0.50) | CA12CA1 | |
| SCHEMBL24454657 | 0.78 | CTSS (0.41) | JAK2 | |
| SCHEMBL18921453 | 0.78 | CTSS (0.41) | JAK2 | |
| SCHEMBL29649069 | 0.78 | CTSS (0.41) | JAK2 | |
| SCHEMBL29641349 | 0.78 | CTSS (0.41) | JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108602809-B | Isoxazolidine derived inhibitors of receptor interacting protein kinase 1(RIPK 1) | 戴纳立制药公司 | 2022-09-30 | — | — | CN | disclosed |